Despite anticipated increased risk of COVID-19 and increased expression of the SARS CoV-2 receptor (ACE2), the relatively low mortality of pregnant women with COVID-19 has been an area of wonder. The immunological changes predominantly inclining to anti-inflammatory state, which is augmented by placental hormones’ immune modulating action, looks against with COVID-19 inflammatory reaction leading to cytokine storm and multiple organ failure. Unlike many other viral infections, the bilateral immune activation of COVID-19 may preferentially make pregnant women at low risk. Taking the physiological advantage of pregnant women, potential clinical trials are proposed. Quite a large number of epidemiological and obstetrics related studies have addressed the cases of women with COVID-19. However, to the best of the author's knowledge, little is done to explore the physiological internal milieu of pregnant women in relation to COVID-19. This review provides an insight into how the hormonal and immunological changes in pregnancy potentially reduce SARS-CoV-2-mediated inflammatory response.

尽管预计 COVID-19 的风险会增加并且 SARS CoV-2 受体 (ACE2) 的表达会增加，但患有 COVID-19 的孕妇死亡率相对较低一直是一个令人惊奇的领域。免疫学变化主要倾向于抗炎状态，胎盘激素的免疫调节作用增强了这种状态，这与导致细胞因子风暴和多器官衰竭的 COVID-19 炎症反应背道而驰。与许多其他病毒感染不同，COVID-19 的双侧免疫激活可能优先使孕妇处于低风险状态。利用孕妇的生理优势，提出了潜在的临床试验。相当多的流行病学和产科相关研究已经解决了患有 COVID-19 的女性病例。然而，据作者所知，很少有人探索孕妇与 COVID-19 相关的生理内部环境。这篇综述深入了解了怀孕期间的激素和免疫学变化如何潜在地减少 SARS-CoV-2 介导的炎症反应。